Generic Evamist Availability
EVAMIST (estradiol - spray;transdermal)
Manufacturer: PERRIGO PHARMA INTL
Approval date: July 27, 2007
Strength(s): 1.53MG/SPRAY [RLD]
Has a generic version of Evamist been approved?
No. There is currently no therapeutically equivalent version of Evamist available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Evamist. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Issued: December 27, 2005
Inventor(s): Wong; Kon Euan & Bayly; Mark Simon
Assignee(s): Acrux DDS Pty Ltd
Hand-held dispensing devices for dispensing and applying a substance to the skin of a host are described. The devices include a hollow body, a capsule mounted within the hollow body for containing the substance, a nozzle mounted within the hollow body communicating with the substance in the capsule, an actuator to cause metered quantities of the substance to be dispensed from the capsule through the nozzle, a shroud defining an exit space for receiving the substance emerging from the nozzle, and a cap detachably mounted on the shroud to selectively open and close the nozzle and thereby control escape of the substance from the capsule.
Patent expiration dates:
- July 31, 2022✓
- July 31, 2022
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Evamist (estradiol)
- Evamist Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 16 Reviews
- Drug class: estrogens
- FDA Alerts (3)
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|